Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/22/2013

Company Name Symbol %Change
ALLIANCE FIB AFOP
9.31%
SONIC FOUNDR SOFO
7.77%
TRI TECH HOL TRIT
6.62%
A M R CP AAMRQ
4.52%
FLOWERS FOOD FLO
4.31%

Huntsman Boosts MDI Capacity

by Zacks Equity Research

August 13, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Huntsman Corporation ( HUN - Snapshot Report ) recently announced that it has conducted engineering studies to expand the Polyurethanes’ methylene diphenyl diisocyanate (MDI) capacity at its Geismar, Louisiana facility.

In order to meet strong demand for residential and commercial insulation, Huntsman is seeking several options to expand the Geismar facility. The company expects the global market for MDI urethanes to grow strongly into the next decade.

Huntsman seeks to maintain its position as the leading MDI supplier in the Americas. It also expects that the investment in the United States will complement its previously announced expansion in China.

In August 2012, Huntsman released its second quarter 2012 results. The company’s adjusted earnings of 58 cents a share beat the Zacks Consensus Estimate of 54 cents. The results were also ahead of the prior-year adjusted earnings of 48 cents.

Net income, as reported, increased 9% to $124 million or 52 cents per share in the quarter from $114 million or 47 cents per share in the year-ago period.

The improvement in earnings was driven by growth in the company’s Polyurethanes business, which grew 12% on a year-over-year basis, along with the restructuring efforts undertaken by the company. These restructuring measures facilitated a 14% year-over-year improvement in its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) to $365 million in the quarter.

However, Huntsman’s revenues remained almost flat on a year-over-year basis at $2,914 million and missed the Zacks Consensus Estimate of $3,077 million.

Huntsman expects earnings from its Pigments business in 2012 to be below the 2011 levels. It also expects prices to decline further due to high inventory levels of titanium dioxide in the market.

Moreover, titanium-bearing ores are expected to become costlier in the third quarter. These factors might have a negative impact of $350 per ton on margins in the third quarter. In addition, weak demand from Europe will hamper Huntsman’s results in the third quarter.

Huntsman, which competes with The Dow Chemical Company ( DOW - Analyst Report ) and BASF SE ( BASFY ) , currently carries a Zacks #3 Rank, reflecting a short-term (1 to 3 months) Hold rating.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.